Sorry!! The article you are trying to read is not available now.
Johnson & Johnson (NY: JNJ)
98.96 USD  UNCHANGED
Streaming Delayed Price  /  Updated: 6:40 PM EDT, Apr 17, 2014  /  Add to My Watchlist      
(JNJ) Community Analysis from
April 19, 2014
(Jutia Group, 4/15/14)
[Seeking Alpha] - Good morning and welcome to the Johnson & Johnson First Quarter 2014 Earnings Conference Call. I would now...(read more)
(Jutia Group, 4/1/14)
[PR Newswire] - BETHESDA, Md., April 1, 2014 /PRNewswire/ -- Johnson & Johnson (JNJ) announced it has entered a multi-year agreement to be...(read more)
(Gold Stocks Today, 1/6/14)
In the wacky world of American politics, if an employer has a religious objection to paying for an employee's contraceptives, it is the employer who is contemptuous of religious freedom. Go figure. But, as...(read more)
JOHNSON & JOHNSON (JNJ) Company Overview
Johnson & Johnson (NYSE:JNJ) is the world's second largest and most broadly based manufacturer of health care products, with 2010 annual sales of $61.6 billion, a decline of 0.5% from 2009. The company holds a significant share of the consumer and pharmaceutical markets, and is the world's largest developer and manufacturer of medical treatment and diagnostic devices.

The consumer health market size is increasing as consumers are taking greater responsibility and interest in their own health. Johnson & Johnson owns highly successful brands such as Tylenol, Band-Aid, and Neutrogena. The acquisition of Pfizer's Consumer Healthcare division in 2006 and addition of brands such as Listerine, Lubriderm, Visine, and Neosporin further solidified Johnson & Johnson dominance in consumer health care. Recently however the company has been plagued by a series of product-quality problems, mainly at its McNeil Consumer Healthcare unit, which makes over-the-counter medicines. The company has recalled Tylenol, Motrin, Benadryl and other products for problems ranging from musty odors that caused nausea in consumers, to excessive concentrations of active ingredients. [1] The problems with manufacturing have hurt the company's bottom line. In 2010, the company suffered significant losses in this segment with a decrease of 7.7% in revenue over the previous year. [2]

The company's pharmaceutical segment faces many of the challenges that face all pharmaceutical companies, including issues surrounding patent expiration and FDA approval. Johnson & Johnson's pharmaceutical segment maintained its revenue numbers as seen in 2009 with only a 0.6% decline in 2010.[2]

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here

WHAT'S POPULAR IN THE VILLE